We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Glucose Monitoring System Designed for Accuracy

By LabMedica International staff writers
Posted on 29 Jul 2013
Recently more attention has been drawn to the accuracy requirements for blood glucose monitoring systems (BGMS) for home use as well as those for hospital use.

Tighter accuracy criteria are being introduced internationally for BGMS and therefore newer systems need to be evaluated for point-of-care testing (POCT) of blood glucose, a valuable biomarker for the management of patients with diabetes and other conditions. More...


Collaborating scientists from three different institutions and the commercial manufacturer evaluated a BGMS in a multicenter study for precision, interference, and system accuracy using 503 blood samples from capillary, venous, and arterial sources. Included in the study was interference testing, both hematocrit and other substances, and accuracy evaluations. The institutes were the Rainier Clinical Research Center (Renton, WA, USA), the Duke University Medical Center (Durham, NC, USA), and MassResearch LLC (Waltham, MA, USA).

The FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System (Abbott Diabetes Care; Alameda, CA, USA) is designed to simplify POCT for healthcare professionals, providing features that enhance the reliability of the testing process and support compliance with POCT policies. The FreeStyle Precision Pro blood glucose-test strip is individually sealed, and each test strip contains three electrodes, working, reference, and fill trigger. The circuit between the fill trigger and the reference electrodes must be detected by the meter before the test will start. The minimum sample volume required is 0.6 μL and the test time is five seconds.

The FreeStyle Precision Pro system demonstrated acceptable precision, no interference across a hematocrit range of 15% to 65%, and, except for xylose, no interference from 24 of 25 potentially interfering substances. From the individual results of various blood sample types, 97.3% to 98.9% agreed within ±12 mg/dL of the laboratory analyzer values at glucose concentrations less than 100 mg/dL and within ±12.5% of the laboratory analyzer values at glucose concentrations equal to or greater than 100 mg/dL.

The authors concluded that the FreeStyle Precision Pro system makes more measurements and uses more signals from the glucose electrochemical reaction to increase accuracy; it also performs more integrity checks to detect potential errors during each glucose test. The study was published on June 5, 2013, in the journal Clinica Chimica Acta.

Related Links:

Rainier Clinical Research Center
Duke University Medical Center
Abbott Diabetes Care



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.